Startup MDx Firm Sequenta Raises $13M in Series B

Leveraging the "absurd revolution in DNA sequencing costs" over the past decade, the San Francisco-based firm is developing an assay for interrogation of the immune repertoire.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories